Physician profile
Indrani E Acosta
NPI 1962699892
$21,658.16
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $627 · 2021: $353 · 2022: $446 · 2023: $131 · 2024: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $288.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $19,086.65 | 2019 | |
| Medtronic Vascular, INC. | $778.97 | 2019-2020 | |
| Viz.Ai, INC. | $207.74 | 2021-2022 | |
| Medtronic USA, INC. | $174.96 | 2019 | |
| Averitas Pharma INC. | $158.12 | 2024 | Qutenza |
| Ceribell, INC. | $142.85 | 2021 | |
| Greenwich Biosciences, INC. | $126.70 | 2019 | |
| Allergan, INC. | $124.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $122.67 | 2019 | |
| Amgen INC. | $121.85 | 2021 | |
| Alexion Pharmaceuticals, INC. | $121.73 | 2022 | |
| Abbvie INC. | $121.53 | 2022 | |
| Microtransponder, INC. | $112.05 | 2023 | |
| Horizon Therapeutics Plc | $83.31 | 2022 | |
| Harmony Biosciences LLC | $80.35 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $75.10 | 2019 | |
| Pfizer INC. | $18.59 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indrani Acosta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.